Six months after the federal government moved to reschedule medical cannabis, the Drug Enforcement Administration’s first list of applicants offers an early look at how state-licensed businesses are responding. DEA recorded 6,983 timely applications, but the response has been far from uniform. Some states generated applications approaching their entire medical license populations; others saw comparatively little activity.
Emerald Intel tracks 20,820 active, medical-designated cannabis licenses nationwide. DEA applications are equivalent to 33.5% of that license universe, although applications and licenses do not necessarily correspond one-to-one. Oklahoma, Florida, and California account for nearly 58% of all applications, but their relative application levels differ substantially.
Oklahoma leads with 2,442 applications, or 35% of the national total. Florida follows with 812 and California with 771. Together, these states account for 4,025 filings. Raw totals, however, tell only part of the story. Comparing applications with active medical-designated licenses highlights differences in market structure and the response to federal rescheduling.
Florida and Pennsylvania stand out for their high number of applications relative to active medical licenses, at 95.5% and 88.7%, respectively. Both are comparatively concentrated medical markets. Oklahoma presents a different picture: its 2,442 applications equal 71.1% of licenses in a state historically characterized by thousands of smaller operators.
By contrast, California recorded applications equivalent to just 17.4% of its medical-designated licenses, while Maine was at 19.7%. Michigan, Oregon, and Montana together accounted for only 103 applications against 3,660 active medical-designated licenses.
These differences may reflect the structure of each state’s industry, the balance between medical and adult-use operations, and the business decisions involved in entering a federal regulatory framework. The application data alone cannot isolate the cause. State license designs also vary: one license may cover multiple facilities, while federal registrations can be location-specific. Accordingly, these figures are comparisons, not verified participation rates.
Dispensaries represent 4,197 applications (60%) of the DEA list. Manufacturers account for 2,076 (30%) and distributors for 710 (10%). The mix shows where the initial filings are concentrated, but it does not by itself establish that dispensaries are more inclined to participate.
The expedited application opportunity was a single 60-day window following the spring rescheduling action. DEA introduced dedicated application procedures for manufacturers, distributors, and laboratories in October, after that window had closed; those procedures did not create another timely application window. It would therefore be misleading to attribute the makeup of the timely-applicant list simply to October’s new forms.
The process has already moved beyond applications. On October 30, the Department of Justice reported that DEA had begun issuing registrations to medical marijuana dispensaries and was reviewing manufacturer and distributor applications. The next question is how application patterns translate into approved federal registrations across states and activities.
The first 6,983 filings make one point clear: the industry’s response to medical cannabis rescheduling is far from uniform. Tracking that response alongside state licensing data will help explain how the regulated market evolves as federal registrations are issued.
Data note: DEA Medical Marijuana Timely Applicants, October 30, 2026; Emerald Intel active medical-designated license data. Applications-to-license percentages are comparative benchmarks, not verified operator participation rates.